Validation and benchmarking of targeted panel sequencing for cancer genomic profiling
American Journal of Clinical Pathology · 2023
DOI: 10.1093/ajcp/aqad078 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2023. Verfasst von Duo Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of …. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Objectives
To validate a large next-generation sequencing (NGS) panel for comprehensive genomic profiling and improve patient access to more effective precision oncology treatment strategies.
Methods
OncoPanScan was designed by targeting 825 cancer-related genes to detect a broad range of genomic alterations. A practical validation strategy was used to evaluate the assay’s analytical performance, involving 97 tumor specimens with 25 paired blood specimens, 10 engineered cell lines, and 121 artificial reference DNA samples.
Results
Overall, 1107 libraries were prepared and the sequencing failure rate was 0.18%. Across alteration classes, sensitivity ranged from 0.938 to more than 0.999, specificity ranged from 0.889 to more than 0.999, positive predictive value ranged from 0.867 to more than 0.999, repeatability ranged from 0.908 to more than 0.999, and reproducibility ranged from 0.832 to more than 0.999. The limit of detection for variants was established based on variant frequency, while for tumor mutation burden and microsatellite instability, it was based on tumor content, resulting in a minimum requirement of 20% tumor content. Benchmarking variant calls against validated NGS assays revealed that variations in the dry-bench processes were the primary cause of discordances.
Conclusions
This study presents a detailed validation framework and empirical recommendations for large panel validation and elucidates the sources of discordant alteration calls by comparing with “gold standard measures.”
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing, China.
- National Center for Clinical Laboratories, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, China.
- Genetron Health (Beijing), Beijing, China.
ORCID-Profile: Rui Zhang
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Wang, D., Wang, S., Zhang, Y., Cheng, X., Huang, X., Han, Y., Chen, Z., Liu, C., Li, J., & Zhang, R. (2023). Validation and benchmarking of targeted panel sequencing for cancer genomic profiling. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqad078
Vancouver
Wang D, Wang S, Zhang Y, Cheng X, Huang X, Han Y, et al. Validation and benchmarking of targeted panel sequencing for cancer genomic profiling. American Journal of Clinical Pathology. 2023. doi:10.1093/ajcp/aqad078
BibTeX
@article{Wang2023,
author = {Wang, Duo and Wang, Sizhen and Zhang, Yuanfeng and Cheng, Xiaolei and Huang, Xin and Han, Yanxi and Chen, Zhaohui and Liu, Cong and Li, Jinming and Zhang, Rui},
title = {Validation and benchmarking of targeted panel sequencing for cancer genomic profiling},
journal = {American Journal of Clinical Pathology},
year = {2023},
doi = {10.1093/ajcp/aqad078}
}
EUVIMED